PT - JOURNAL ARTICLE AU - Marisol Perez-Toledo AU - Sian E. Faustini AU - Sian E. Jossi AU - Adrian M. Shields AU - Hari Krishnan Kanthimathinathan AU - Joel D. Allen AU - Yasunori Watanabe AU - Margaret Goodall AU - David C. Wraith AU - Tonny V. Veenith AU - Mark T. Drayson AU - Deepthi Jyothish AU - Eslam Al-Abadi AU - Ashish Chikermane AU - Steven B. Welch AU - Kavitha Masilamani AU - Scott Hackett AU - Max Crispin AU - Barnaby R Scholefield AU - Adam F. Cunningham AU - Alex G. Richter TI - Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with Paediatric Inflammatory Multi-System Syndrome AID - 10.1101/2020.06.05.20123117 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.05.20123117 4099 - http://medrxiv.org/content/early/2020/06/07/2020.06.05.20123117.short 4100 - http://medrxiv.org/content/early/2020/06/07/2020.06.05.20123117.full AB - Background During the COVID-19 outbreak, reports have surfaced of children who present with features of a multisystem inflammatory syndrome with overlapping features of Kawasaki disease and toxic shock syndrome – Paediatric Inflammatory Multisystem Syndrome-temporally associated with SARS-CoV-2 pandemic (PIMS-TS). Initial reports find that many of the children are PCR-negative for SARS-CoV-2, so it is difficult to confirm whether this syndrome is a late complication of viral infection in an age group largely spared the worst consequences of this infection, or if this syndrome reflects enhanced surveillance.Methods Children hospitalised for symptoms consistent with PIMS-TS between 28 April and 8 May 2020, and who were PCR-negative for SARS-CoV-2, were tested for antibodies to viral spike glycoprotein using an ELISA test.Results Eight patients (age range 7–14 years, 63% male) fulfilled case-definition for PIMS-TS during the study period. Six of the eight patients required admission to intensive care. All patients exhibited significant IgG and IgA responses to viral spike glycoprotein. Further assessment showed that the IgG isotypes detected in children with PIMS-TS were of the IgGl and lgG3 subclasses, a distribution similar to that observed in samples from hospitalised adult COVID-19 patients. In contrast, lgG2 and lgG4 were not detected in children or adults. IgM was not detected in children, which contrasts with adult hospitalised adult COVID-19 patients of whom all had positive IgM responses.Conclusions Strong IgG antibody responses can be detected in PCR-negative children with PIMS-TS. The low detection rate of IgM in these patients is consistent with infection having occurred weeks previously and that the syndrome onset occurs well after the control of SARS-CoV-2 viral load. This implies that the disease is largely immune-mediated. Lastly, this indicates that serology can be an appropriate diagnostic tool in select patient groups.Competing Interest StatementAuthors declare no competing interests except for Dr. Mark Drayson who owns shares in Abingdon Health.Funding StatementAFC is grateful for funding from The Medical Research Council and The Institute for Global Innovation, The University of Birmingham for funding. This study was supported by the UK National Institute for Health Research, Birmingham Biomedical Research Centres Funding scheme. Dr Barnaby Scholefield is funded by the NIHR Clinician Scientist fellowship programme. The work in Prof. Max Crispin's laboratory was funded by the International AIDS Vaccine Initiative, Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (OPP1084519 and OPP1115782), the Scripps Consortium for HIV Vaccine Development (CHAVD) (AI144462), and the University of Southampton Coronavirus Response Fund which has over 1000 donors from around the world.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical approval for this work and the use of these samples was provided by the awarding bodies of the University of Birmingham Research Ethics Committee, the South Birmingham Research Ethics Committee and the National Research Ethics Service Committee West Midlands. All approvals are overseen by the United Kingdom National Health Service and this is therefore a NHS Health Research Authority approved study. All patients and/or their parents/legal guardians provided signed informed consent to inclusion of de-identified data in this report.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.